Shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report) saw an uptick in trading volume on Monday . 64,083 shares traded hands during trading, an increase of 146% from the previous session’s volume of 26,033 shares.The stock last traded at $18.12 and had previously closed at $18.40.
Analysts Set New Price Targets
TLX has been the topic of a number of research analyst reports. UBS Group raised their target price on Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the company a “buy” rating in a report on Monday, January 27th. William Blair restated an “outperform” rating on shares of Telix Pharmaceuticals Limited American Depositary Shares in a research note on Wednesday.
Get Our Latest Analysis on TLX
Telix Pharmaceuticals Limited American Depositary Shares Trading Up 2.4 %
About Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Featured Stories
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- Why Invest in High-Yield Dividend Stocks?
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- What Does Downgrade Mean in Investing?
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- Golden Cross Stocks: Pattern, Examples and Charts
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
